Swedish pharmaceutical company Recipharm has signed a long-term manufacturing agreement with Roche to produce a wide range of solid dose products.
Under the deal, the company will also purchase a manufacturing facility from Roche.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLocated in Leganés, Spain, the well-equipped manufacturing factory currently employs approximately 200 people and develops solid dose products.
The facility is licensed to supply products to more than 95 countries worldwide.
The long-term manufacturing agreement will add Recipharm’s annual sales of approximately €35m with the company’s overall target.
Recipharm chief executive officer Thomas Eldered said: “We are continuing to gain momentum in the contract development and manufacturing organisation (CDMO) market through our various profitable growth initiatives.
“I am therefore delighted to announce this long-term agreement with Roche. It has become clear during our interactions with Roche that we are closely aligned in our ways of doing business, and we look forward to developing this relationship further by providing high-quality, reliable supplies from Leganés in future.
“In addition, we see a highly interesting business development opportunity to add new customers.”
The acquisition of the solid dose products factory and the performance of the manufacturing agreement will be organised in a wholly owned subsidiary of Recipharm.
Closing of the transaction and initiation of the product supply is expected by the end of this year.
